Case Report: When multiple system atrophy masquerades as CASPR2 autoimmune encephalopathy: a diagnostic pitfall

Jun Zhang, Yueming Wang, Le Chen, Jun LiFrontiers in Human Neuroscience 2025 · DOI

TL;DR

This case report details a diagnostic "red herring" where a patient with Multiple System Atrophy (MSA) presented with high-titer CASPR2 antibodies, typically indicative of a treatable autoimmune condition. The study emphasizes that clinical progression and specialized electrophysiology (EAS-EMG) must take precedence over isolated lab results to avoid misdiagnosis in complex neurodegenerative disorders.

What Problem Does This Paper Address?

The early diagnosis of Multiple System Atrophy (MSA), specifically the cerebellar subtype (MSA-C), is notoriously difficult because its hallmark symptom—autonomic dysfunction—often appears late in the disease course.

In this case, the diagnostic waters were further muddied by the presence of CASPR2 antibodies. CASPR2-related diseases are autoimmune, often treatable with immunotherapy, and can mimic the ataxia seen in MSA. The authors tackle the "diagnostic pitfall" of over-relying on highly specific biomarkers (like a 1:100 antibody titer) when the clinical reality and disease progression suggest a different, more aggressive neurodegenerative path.

Methods

The authors employed a longitudinal clinical study of a single 56-year-old female patient over two years. Key diagnostic techniques included:

  • Serological Testing: Cell-based assays (CBA) to detect and titer autoimmune antibodies (NMDA-R, CASPR2, LGI1, etc.).
  • Neuroimaging: Serial brain MRIs to track structural changes in the brainstem and cerebellum.
  • Electrophysiology: External anal-sphincter electromyography (EAS-EMG), a specialized test used to detect subclinical denervation of Onuf’s nucleus—a specific marker for MSA.
  • Therapeutic Trial: A course of high-dose corticosteroids and immunosuppressants (Mycophenolate Mofetil) to see if the patient responded to autoimmune-targeted treatment.

Datasets

As this is a Case Report, it does not utilize a large-scale training dataset. The "data" consists of the patient's clinical history, laboratory results, and imaging. The authors contextualize their findings by referencing existing literature on CASPR2 antibody prevalence (e.g., Becker et al., 2012) and established diagnostic criteria for MSA (Wenning et al., 2022).

Key Insights and Ideas

  • The "Serological-Clinical Dissociation": This is the paper's most critical concept. While immunotherapy successfully lowered the patient's CASPR2 antibody titer from 1:100 to 1:10, her physical condition continued to deteriorate. This dissociation proved the antibodies were likely an "incidental finding" rather than the primary cause of the disease.
  • Secondary Immune Response: The authors hypothesize that in neurodegenerative diseases, high-titer autoantibodies may emerge as a secondary immune response triggered by the release of antigens from damaged neurons, rather than being the primary pathogenic driver.
  • EAS-EMG as a "Crystal Ball": The EAS-EMG showed abnormalities (increased motor unit action potential duration and satellite potentials) before the patient developed overt clinical signs of autonomic failure (like urinary issues or orthostatic hypotension). This highlights the test's high sensitivity for early-stage MSA.
  • Genetic Predisposition: The authors suggest that certain HLA alleles (like HLA-DRB1*11:01) might predispose some MSA patients to produce these "incidental" antibodies, though genotyping was not performed in this specific case.

Key Results

  • Initial Misdiagnosis: The patient was initially treated for CASPR2 Autoimmune Encephalopathy due to the high antibody titer.
  • Treatment Failure: Despite aggressive immunotherapy, the patient’s ataxia and speech worsened, and MRI showed progressive brainstem/cerebellar atrophy.
  • Clinical Evolution: One year post-discharge, the patient developed classic MSA symptoms: a >30 mmHg drop in systolic blood pressure (orthostatic hypotension) and frequent urination.
  • Final Diagnosis: The diagnosis was revised to clinically established MSA-C.
  • Quantitative Marker: The EAS-EMG successfully identified neurogenic changes in Onuf’s nucleus, providing early evidence of neurodegeneration that the initial clinical exam missed.

Limitations and Future Work

  • Single Case Study: As a case report, the findings cannot be generalized to all patients with ataxia and CASPR2 positivity without further large-scale cohort studies.
  • Missing Genetic Data: HLA genotyping was not conducted, which could have provided deeper insight into why this specific patient produced high-titer antibodies.
  • Future Directions: The authors call for clinicians to maintain "dynamic follow-up" and suggest that EAS-EMG should be used more broadly in the differential diagnosis of adult-onset ataxia, even when autonomic symptoms are not yet visible.

Summary updated

Abstract

In the early stages of MSA, autonomic nerve dysfunction may not manifest clinically. Therefore, close follow-up is essential for accurate diagnosis. EAS-EMG exhibits high sensitivity in detecting subclinical autonomic dysfunction. Although the co-occurrence of MSA-C and high-titer (1:100) CASPR2-IgG is uncommon, this case highlights the critical importance of relying on the overall clinical presentation, rather than on isolated laboratory findings, to establish the primary diagnosis.
BibTeX
@inproceedings{zhang2025case,
  author = {Jun Zhang and Yueming Wang and Le Chen and Jun Li},
  title = {{Case Report: When multiple system atrophy masquerades as CASPR2 autoimmune encephalopathy: a diagnostic pitfall}},
  booktitle = {Frontiers in Human Neuroscience},
  year = {2025},
  doi = {10.3389/fnhum.2025.1658933},
}
Figure